SGLT2 inhibitors and nephrolithiasis risk: a meta-analysis.

ABSTRACT:

Background

Sodium-glucose co-transporter 2 (SGLT2) inhibitors are novel anti-diabetic medications with potential beneficial effects on cardiovascular and renal outcomes, metabolic parameters and body weight. In addition to the beneficial effects on renal function, including estimated glomerular filtration rate and reduction in proteinuria, recent studies have investigated the potential role of SGLT2 inhibitor (SGLT2i) therapy on nephrolithiasis development. Nephrolithiasis, a condition affecting almost 10% of the general population at least once during a lifetime, is a common disorder with considerable risk for acute and chronic kidney injury and relatively few effective therapeutic options.

Methods

We performed a literature search through multiple databases, including PubMe

SUBMITTER: Kanbay M 

PROVIDER: S-EPMC11997758 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature